Acute Interstitial Nephritis Triggered by a Novel Anti-CD25 Antibody-Drug Conjugate, Camidanlumab Tesirine

Lignende værker

• 608 Results of a phase 1 study investigating camidanlumab tesirine as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors
  af: Igor Puzanov, et al.
  Udgivet: (2023-11-01)
• S201: CAMIDANLUMAB TESIRINE: UPDATED EFFICACY AND SAFETY IN AN OPEN-LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)
  af: C. Carlo-Stella, et al.
  Udgivet: (2022-06-01)
• Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
  af: Bilal H. Lashari, et al.
  Udgivet: (2018-09-01)
• Targeting CD19-positive lymphomas with the antibody-drug conjugate loncastuximab tesirine: preclinical evidence as single agent and in combination therapy
  af: Chiara Tarantelli, et al.
  Udgivet: (2024-05-01)
• Acute interstitial nephritis observed with three different triggering agents
  af: Niloofar Nobakht, et al.
  Udgivet: (2022-03-01)